Literature DB >> 3698003

New screening system for selection of anticancer drugs for treatment of human colorectal cancer.

W Scheithauer, G M Clark, M P Moyer, D D Von Hoff.   

Abstract

We report an evaluation of a new radiometric technique (BACTEC assay) as a potential screening system for cytotoxic compounds with activity against cancer of the large bowel. Exponentially growing cells of nine different human colorectal cancer cell lines were exposed to a variety of standard anticancer agents with or without documented clinical activity. Each drug was tested in a series of 1-h and continuous exposure studies utilizing three different concentrations. Antineoplastic effects were analyzed as a function of in vivo achievable serum concentrations, namely by a ratio of the concentration required to decrease cell growth to 10% of control to one-tenth of the peak plasma concentration in humans. Our results suggest that COLO 320DM, OM-1, and Ht-29 cells manifest responsiveness to anticancer drugs consistent with that noted in clinical studies with most agents tested. The radiometric technique provides several advantages for a screening system, including reproducibility, a good agreement with the cloning assay, speed, and low costs. The combined use of the BACTEC technique and the three colon cancer cell lines could prove useful as a screen for new anticancer compounds with activity in colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3698003

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  A semi-automated neutral red based chemosensitivity assay for drug screening.

Authors:  P F Cavanaugh; P S Moskwa; W H Donish; P J Pera; D Richardson; A P Andrese
Journal:  Invest New Drugs       Date:  1990-11       Impact factor: 3.850

Review 2.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. III. Antimetabolites, tubulin-binding agents, platinum drugs, amsacrine, L-asparaginase, interferons, steroids and other miscellaneous antitumor agents.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Application of a new preclinical drug screening system for cancer of the large bowel.

Authors:  W Scheithauer; M P Moyer; G M Clark; D D Von Hoff
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

4.  An in vitro assessment of the antineoplastic potential of 2H-1,3-oxazine-2,6(3H)-dione (3-oxauracil), a novel pyrimidine.

Authors:  L Seal; D Von Hoff; R Lawrence; E Izbicka; R M Jamison
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

5.  Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.

Authors:  Y Sasaki; T Shinkai; K Eguchi; T Tamura; Y Ohe; T Ohmori; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  A polymer-based drug delivery system for the antineoplastic agent bis(maltolato)oxovanadium in mice.

Authors:  J K Jackson; W Min; T F Cruz; S Cindric; L Arsenault; D D Von Hoff; D Degan; W L Hunter; H M Burt
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.